In 2014, Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), was FDA-approved for use for metastatic and recurrent cervical cancer following the completion of the randomized phase III trial, GOG-240 [23]. This evidence concerns the gene VEGFA and cervical cancer.